Evidence map›Paper›PMID 38091306›Full record

ArticlePloS one2023

The economic burden of households affected by tuberculosis in Brazil: First national survey results, 2019-2021.

Ethel Leonor Noia Maciel, Letícya Dos Santos Almeida Negri, Leticia Molino Guidoni, Geisa Carlesso Fregona, Fernanda Dockhorn Costa Johansen, Mauro Niskier Sanchez, Adriana da Silva Rezende Moreira, Fredi Alexander Diaz-Quijano, Maiko Tonini, Eliana Zandonade and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Temporal trends in incidence and mortality from pulmonary tuberculosis: time series study, Sul da Bahia, 2010-2023.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

Ethel Leonor Noia MacielLaboratory of Epidemiology Federal University of Espírito Santo, UFES, Vitória, ES, Brazil.ORCID 0000-0003-4826-3355
Letícya Dos Santos Almeida NegriFederal University of Espírito Santo, UFES, Vitória, ES, Brazil.ORCID 0000-0002-0056-4506
Leticia Molino GuidoniFederal University of Espírito Santo, UFES, Vitória, ES, Brazil.ORCID 0000-0003-3737-5407
Geisa Carlesso FregonaCassiano Antônio Moraes University Hospital - HUCAM, Vitória, ES, Brazil.
Fernanda Dockhorn Costa JohansenNational TB Programme, Ministry of Health, Brasília, Brazil.
Mauro Niskier SanchezUniversity of Brasília, UNB, Brasília, DF, Brazil.
Adriana da Silva Rezende MoreiraFederal University of Rio de Janeiro, UFRJ, Rio de Janeiro, Brazil.
Fredi Alexander Diaz-QuijanoUniversity of São Paulo, USP, São Paulo, Brazil.
Maiko ToniniUniversity of Brasília, UNB, Brasília, DF, Brazil.
Eliana ZandonadeFederal University of Espírito Santo, ES, Brazil.
Julia ErshovaCenters for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Peter NguhiuKEMRI- Wellcome Trust Research Program, Health Economics Research Unit, Nairobi, Kenya.
Inés Garcia BaenaWorld Health Organization, Global TB Programme, Geneva, Switzerland.
Universidade Federal do Espírito Santo · BRUniversidade de Brasília · BRCenters for Disease Control and Prevention · USHospital Universitário da Universidade de São Paulo · BRKenya Medical Research Institute · KEMinistério da Saúde · BRSanta Casa Hospital · BRUniversidade Federal do Rio de Janeiro · BRWorld Health Organization · CH

Funding

CGH CDC HHS U2G GH001152World Health Organization 001
6 · The paper itself

Abstract

backgroundOne of the three main targets of the World Health Organization (WHO) End TB Strategy (2015-2035) is that no tuberculosis (TB) patients or their households face catastrophic costs (defined as exceeding 20% of the annual household income) because of the disease. Our study seeks to determine, as a baseline, the magnitude and main drivers of the costs associated with TB disease for patients and their households and to monitor the proportion of households experiencing catastrophic costs in Brazil.

methodsA national cross-sectional cluster-based survey was conducted in Brazil in 2019-2021 following WHO methodology. TB patients of all ages and types of TB were eligible for the survey. Adult TB patients and guardians of minors (<18 years old) were interviewed once about costs, time loss, coping measures, income, household expenses, and asset ownership. Total costs, including indirect costs measured as reported household income change, were expressed as a percentage of annual household income. We used descriptive statistics to analyze the cost drivers and multivariate logistic regression to determine factors associated with catastrophic costs.

resultsWe interviewed 603 patients, including 538 (89%) with drug-sensitive (DS) and 65 (11%) with drug-resistant (DR) TB. Of 603 affected households, 48.1% (95%CI: 43-53.2) experienced costs above 20% of their annual household income during their TB episode. The proportion was 44.4% and 78.5% among patients with DS- and DR-TB, respectively. On average, patients incurred costs of US$1573 (95%CI: 1361.8-1785.0) per TB episode, including pre-diagnosis and post-diagnosis expenses. Key cost drivers were post-diagnosis nutritional supplements (US$317.6, 95%CI: 232.7-402.6) followed by medical costs (US$85.5, 95%CI: 54.3-116.5) and costs of travel for clinic visits during treatment (US$79.2, 95%CI: 61.9-96.5). In multivariate analysis, predictors of catastrophic costs included positive HIV status (aOR = 3.0, 95%CI:1.1-8.6) and self-employment (aOR = 2.7, 95%CI:1.1-6.5); high education was a protective factor (aOR = 0.1, 95%CI:0.0-0.9).

conclusionsAlthough the services offered to patients with TB are free of charge in the Brazilian public health sector, the availability of free diagnosis and treatment services does not alleviate patients' financial burden related to accessing TB care. The study allowed us to identify the costs incurred by patients and suggest actions to mitigate their suffering. In addition, this study established a baseline for monitoring catastrophic costs and fostering a national policy to reduce the costs to patients for TB care in Brazil.

Indexed as

TuberculosisTuberculosis, Multidrug-ResistantAdolescentAdultBrazilCosts and Cost AnalysisCross-Sectional StudiesFinancial StressHumansIncome

Identifiers

PMID38091306
PMCPMC10718450
OpenAlexW4389669395

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.